Common Acne Drug May Offer Protection Against Schizophrenia: Study Suggests We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Boehringer Ingelheim and Click Therapeutics have revealed the data from their pivotal trial of digital therapeutic (DTx) CT-155 for schizophrenia, which has shown efficacy against some of the symptoms that are hardest to address with drug therapies. At the European College of Neuropsychopharmacology (ECNP) Congress in Amsterdam this week, the two partners presented data from…
Approximately 7 million children in the United States between the ages of three and 17 have been diagnosed with attention deficit hyperactivity disorder (ADHD), according to the Centers For Disease Control and Prevention. Up to 50% of children with ADHD also have severe problems with impulsive aggression and persistent irritability, according to James Waxmonsky, professor of psychiatry…
The UK’s Royal College of Psychiatrists (RCPsych) has published a report that calls for more clinical testing of psychedelic medicines, as there is currently a lack of “high-quality evidence” to support their use. The report says that this is in part because of legal restrictions around the use of psychedelics in research, including lengthy ethics…
Over five percent of children and adolescents are diagnosed with attention deficit/hyperactivity disorder (ADHD) globally. This condition is characterized by a short attention span, hyperactivity or impulsive behavior that is age-inappropriate, making it difficult for patients to navigate interpersonal relationships, the formal education system, and social life. Researchers have used brain imaging analyses such as…
Akum Pharma Asked to Submit Safety Data for Alzheimer’s Drug Combo In Elderly Indian Patients We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link